Physician profile
Chad Turner
NPI 1245204510
$10,826.43
in general payments reported to CMS, 2019-2025
51 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $1,241 · 2021: $1,652 · 2022: $1,602 · 2023: $1,550 · 2024: $1,549 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,765.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,862.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,684.54 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $963.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $578.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $546.67 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $488.21 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $400.93 | 2019-2025 | |
| Astellas Pharma US INC | $346.75 | 2019-2024 | Myrbetriq, Veozah |
| Merck Sharp & Dohme LLC | $292.43 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.15 | 2019-2022 | |
| Pfizer INC. | $283.05 | 2022-2025 | |
| Allergan, INC. | $255.06 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.01 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $210.50 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $210.23 | 2019-2023 | Xarelto |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.